This fixed-dose combination is commonly used to provide supportive relief for symptoms related to the common cold or influenza episode. This formulation is relevant for easing systemic and upper respiratory discomforts. It is applied across domains where additional symptomatic support is needed to ease the overall symptom burden.

The preparation is generally relevant when symptoms cluster into patterns requiring supportive management, specifically covering fever, minor aches, headache, nasal congestion, runny nose, and sneezing. This is helpful in situations where multiple symptoms occur together and create noticeable physiological strain. This provides support that may assist with maintaining a sense of stability when symptoms are more noticeable, and contributes to easing the overall symptom load.

“The primary goal is to provide supportive relief during the acute, uncomfortable phase of seasonal respiratory illness.”

Quick Fact: Relief for Concurrent Symptoms
Systemic Pain	Is used for managing minor aches, headache, and generalized discomfort.
Fever	May assist with reducing elevated body temperature.
Congestion	Is relevant for easing stuffy nose and sinus pressure.
Rhinorrhea	Is applied in addressing runny nose and sneezing.

Regulatory References

1. DailyMed Label for Theraflu Cold and Flu

Population Eligibility Rules

The eligibility for using the medicine ТераФлю is strictly defined by regulatory criteria, establishing both the approved user population and absolute exclusions. The medication is officially intended for adults and children 12 years of age and over. It is contraindicated for use in children under 12 years of age.

---

Absolute Contraindications

The medicine must not be used by individuals with known hypersensitivity to any component or those currently taking, or who have taken within the past two weeks, a Monoamine Oxidase Inhibitor (MAOI). Use is also prohibited for patients consuming any other medicine containing acetaminophen. Furthermore, individuals with specific chronic conditions, including portal hypertension, diabetes mellitus, hyperthyroidism, or angle-closure glaucoma, are contraindicated from use, as stated in regulatory labeling.

---

Use Under Restricted Circumstances

Certain populations must only use the medicine with caution or after consultation, as directed by labeling. This includes patients with severe liver disease or severe renal impairment, heart disease, high blood pressure, and those experiencing trouble urinating due to an enlarged prostate gland. Use during pregnancy and breastfeeding is also placed into a restricted or contraindicated category by official documents.

The official interaction profile for this combination medicine is primarily defined by high-severity prohibited combinations and specific administration restrictions. Co-administration is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs), requiring a two-week separation after discontinuing the MAOI. The preparation is also strictly prohibited for use with any other medicine containing acetaminophen to mitigate the severe risk of overdose and liver damage. Other contraindicated combinations noted in regulatory documents include Beta-adrenergic blockers, Tricyclic Antidepressants, and other Sympathomimetic Decongestants.

A major pharmacodynamic constraint involves substances causing additive Central Nervous System (CNS) effects. Co-administration with alcohol (ethanol), sedatives, tranquilizers, or opioid pain relievers may result in increased marked drowsiness and should be avoided. The interaction profile further highlights metabolic constraints related to Acetaminophen. Co-use with liver enzyme-inducing drugs (such as Carbamazepine or Rifampicin) is associated with an increased hazard of hepatotoxicity, especially in cases of overdose.

The official label also notes that Acetaminophen may increase the blood-thinning effect of oral anticoagulants like Warfarin, necessitating caution. Separately, administration requires spacing from Colestyramine to avoid a reduction in absorption. Specific population notes indicate that the risk of Acetaminophen-related liver damage is greater for patients with alcoholism or those identified as Glutathione-depleted.

Central Enzyme Inhibition and Thermoregulatory Modulation

Acetaminophen operates by acting as a central enzyme inhibitor, selectively reducing the synthesis of Prostaglandin E2 (PGE2) within the hypothalamus. By modifying this key signaling mediator, the mechanism influences the neural pathways that control the body's thermoregulatory set-point, thereby facilitating heat dissipation and modulating nociceptive signaling.

---

Coordinated Control of Mucosal Vasculature

Mucosal volume is regulated through two distinct, complementary pathways. Phenylephrine acts as a direct agonist of mathbfalpha1-Adrenergic Receptors on vascular smooth muscle, initiating contraction (vasoconstriction) and reducing tissue blood volume. Concurrently, Pheniramine blocks mathbfH1-Receptors, limiting histamine-driven capillary leakage and fluid extravasation. This multitargeted action induces detumescence (shrinking) of the nasal mucosa.

---

Histamine Receptor Blockade and Secretion Modulation

This mechanistic domain involves Pheniramine Maleate acting as a competitive antagonist at peripheral mathbfH1-Receptors. By occupying these receptors on sensory nerves and endothelial cells, the drug limits the binding of naturally released histamine. This action stabilizes capillary permeability and dampens sensory nerve over-stimulation, thereby modulating fluid secretion and sensory signaling.

Official Administration Guidelines

The usage of the multicomponent ТераФлю powder for oral solution is based on established protocols for these fixed-dose combinations. The protocol defines the required steps for preparation, the standardized single dose, and the restrictions on frequency and duration of use.

Administration Scope	Official Instruction
Route of Administration	Oral administration only, following mandatory dilution.
Standard Dosing Unit	One packet (sachet) is the standard dose for individuals 12 years of age and older.
Frequency and Limit	Doses are taken every 4 hours or 6 hours, strictly while symptoms persist. Do not exceed 5 to 6 packets (depending on the specific product formulation) in a 24-hour period.
Age-Group Rule	Restricted to Adults and children 12 years of age and older. Children under 12 years of age: Do Not Use.
Course Duration	Use is limited to short-term, symptomatic relief. The regimen should be discontinued once temporary symptoms are relieved.

Preparation and Procedural Structure

The official instructions mandate specific steps for preparing the powder for oral solution:

• Dissolve: The entire contents of one packet must be completely dissolved into 8 ounces (approx 240 mL) of hot water.
• Intake: The prepared solution must be sipped while hot, with the entire drink consumed within 10–15 minutes of preparation.

This structured protocol establishes the procedure for using the medicine. The administration is entirely contingent on the persistence of acute symptoms and is subject to the stated maximum limits.

Research Evidence / Overview of Studies for ТераФлю

---

Evidence for Symptomatic Relief of the Common Cold

The primary evidence available for this combination medicine consists of short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time when the combination was administered compared to a placebo (an inactive treatment). The research primarily examined outcomes related to physical discomfort and outcomes describing episodic or acute changes in adult populations diagnosed with a common cold. Studies explored conditions associated with periods of heightened symptoms and monitored measurements of overall symptom scores.

While evidence contributes to understanding symptom patterns, there is limited and inconsistent data related to the findings of the oral decongestant component, Phenylephrine. Regulatory reviews have indicated that the findings were mixed regarding its role in nasal congestion relief in some contexts, meaning certainty appears low for that specific aspect. The existing studies provide limited insight into whether the combination influences the overall duration of the common cold illness itself.

---

Evidence for Symptomatic Relief of Flu-like Syndrome

The combination was studied for managing the collection of symptoms associated with acute flu-like illness, which are conditions involving periods of heightened symptoms. The evidence primarily stems from trials where the expected effects of its analgesic-antipyretic component (Acetaminophen) were observed in relation to changes in body temperature and pain scores. Studies report that the overall perceived discomfort, which includes patient-reported outcomes describing perceived discomfort, data show patterns related to changes in the observed groups compared to those taking placebo.

Crucially, the evidence does not address whether the use of this symptomatic combination influences the course of the underlying viral infection or affects the rate of viral clearance. Data show patterns related to symptom management, but comparative evidence is lacking regarding its effectiveness versus other specific single-ingredient treatments for flu-like syndrome.

---

Long-Term Studies and Follow-Up Duration

The clinical research available for this fixed-dose combination has generally not examined long-term outcomes. The primary focus is on research exploring short-term symptom changes over the acute phase of the illness, typically the first three to five days. The follow-up durations were limited in most key studies, and long-term effects are not characterized by the short-term evidence.

---

Evidence in Specific Populations

Research examining the combination was observed in primarily healthy adults (18–65 years old). Consequently, the data for certain groups remain insufficient. For populations such as older adults, those with complex or chronic health conditions, or children and adolescents, there are relatively few dedicated data sets specifically for this exact fixed-dose combination. Therefore, the results apply only to the populations studied in the comparative trials.

---

What Remains Uncertain About the Research Landscape

In addition to the limited long-term data, subgroup findings are uncertain due to the focus of most trials on healthy adult populations. The available evidence, while documenting short-term symptom changes, does not determine whether the combination examines outcomes related to preventing complications or secondary infections. Researchers continue to explore the optimal ways to manage episodic symptoms, but the full scope of the combination's effects beyond short-term symptomatic relief remains a subject where research is ongoing and findings are still emerging.

Key Studies & References THERAFLU COLD AND FLU - DailyMed (Label for Acetaminophen, Pheniramine Maleate, Phenylephrine HCl Powder)

Common questions about ТераФлю (FAQ)

---

Q: Is ТераФлю intended for treating the flu or a common cold?

According to the official product information, ТераФлю is described as a symptomatic treatment. Its purpose is the systemic relief of discomforts associated with the common cold and flu. It is not classified as an antiviral medication intended to treat or cure the underlying viral infection itself.

---

Q: Can ТераФлю cause drowsiness or affect driving ability?

Regulatory documents state that the medicine may cause drowsiness or dizziness, which is listed as a very common side effect due to the antihistamine component. The labeling indicates that individuals should assess how the medicine affects them prior to operating machinery or driving.

---

Q: Can I take ТераФлю if I am already taking a medication for blood pressure?

Official labeling advises caution or consultation before use by patients with high blood pressure. The official documentation also highlights certain specific types of blood pressure medications, like Beta-adrenergic blockers, that are contraindicated for co-use.

---

Q: Does ТераФлю interact with alcohol, and if so, how?

Official product information documents that co-administration with alcohol (ethanol) may result in an increased risk of marked drowsiness. The combination is also noted to increase the hazard of liver toxicity, especially due to the Acetaminophen component.

---

Q: Is it described anywhere if ТераФлю is suitable for use by older adults?

Official texts note that older adults may experience increased sensitivity to some adverse effects. Official texts mention that effects such as dizziness and confusion may be experienced with increased sensitivity in this population.

---

Q: What is the difference between ТераФлю for Flu and ТераФлю Night?

Differences between product variants are described by changes in the formulation's active ingredients. Regulatory databases show that 'Night' versions often contain an additional sedative-type antihistamine, while 'Flu' versions are typically formulated to be less sedating.

---

Q: Is there research evidence supporting the combination of ingredients in ТераФлю?

Studies and official information indicate that the evidence primarily consists of short-term randomized controlled trials (RCTs). These trials examined changes in overall symptom scores compared to a placebo in healthy adults experiencing acute cold and flu-like symptoms.

---

Q: How quickly is the onset of action expected after taking ТераФлю?

The powder for oral solution form is intended to achieve rapid systemic absorption after dilution in hot water. According to pharmacokinetics data, the pain-relieving effects of the Acetaminophen component are typically noted to begin within 30 minutes of ingestion.

---

Q: How long does the effect of one dose of ТераФлю usually last?

The general duration of effect for a single dose is inferred from the administration instructions defined in regulatory labeling. Dosing frequency is typically described as being every four to six hours.

---

Q: Is ТераФлю considered to be a pain reliever or just a cold symptom treatment?

ТераФлю is classified as a fixed-dose combination (FDC) drug. The formulation is intended to provide simultaneous relief, as it combines an analgesic-antipyretic (pain and fever reliever) with an antihistamine and a decongestant for integrated cold/flu symptom management.

---

Q: Why do official documents mention specific warnings for people with liver conditions?

The warnings are specifically related to the Acetaminophen component of the medicine. Regulatory documents emphasize that Acetaminophen carries a documented risk of severe liver damage, especially in cases of overdose or when co-used with liver enzyme-inducing agents.

---

Q: Can ТераФлю be taken if a person has certain kidney problems?

Official regulatory labeling places patients with severe renal impairment (severe kidney problems) into a category that requires caution. Official guidance suggests consulting a healthcare professional is necessary for patients in this category.

---

Q: What is the role of pheniramine maleate in some ТераФлю formulations?

Pheniramine maleate is the antihistamine component of the preparation. Its primary role is to mitigate the symptoms that are linked to histamine release, such as sneezing, watery eyes, and runny nose.

---

Q: Is the use of ТераФлю described in patients who are breastfeeding?

Regulatory documents place the use of the medicine during breastfeeding into a restricted or contraindicated category. This categorization is based on official descriptions of the potential for the active ingredients to be excreted in breast milk.

---

Q: Does taking ТераФлю require drinking a certain amount of water?

The administration instructions found in official labeling are highly specific. They mandate dissolving the entire contents of one powder packet into 8 ounces (approximately 240 mL) of hot water before consumption.

---

Q: Does ТераФлю contain any ingredients that might be restricted for competitive athletes?

The preparation contains the ingredient Phenylephrine Hydrochloride, which is classified as a sympathomimetic agent. Use by athletes may require verification of the ingredient's status with relevant sports regulatory bodies.

---

Q: Does ТераФлю contain aspirin?

No, the official composition of the medicine does not contain aspirin. The active ingredients listed in the product composition are Acetaminophen, Pheniramine Maleate, and Phenylephrine Hydrochloride.

---

Q: Is there a sugar-free version of ТераФлю?

Yes, according to the official product information, there are several formulations available. Many versions of the powder for oral solution contain excipients like sucralose or saccharin sodium in place of sugar, and these are documented as 'sugar-free'.

---

Q: How is the use of ТераФлю described for people with diabetes?

Official regulatory documents state that the medicine is contraindicated for use by individuals diagnosed with diabetes mellitus. A contraindication indicates the medicine should not be used by this population.

---

Q: Can ТераФлю be used if someone has glaucoma?

Official regulatory documents state that the medicine is contraindicated for use by individuals diagnosed with angle-closure glaucoma. This classification defines the medicine as inappropriate for use by this population.

---

Q: Is it normal if I feel a bit restless after taking ТераФлю?

Adverse reactions listed in official documents under Nervous System Disorders include states such as dizziness, nervousness, or excitation. These effects are possible side effects that a person might perceive as feeling restless.

---

Q: Can ТераФлю affect test results for any medical conditions?

Official warnings indicate that Acetaminophen, one of the active ingredients, has been documented to potentially interfere with the results of certain laboratory tests. This may include tests used for monitoring blood glucose levels.

---

Q: Is there information about the use of ТераФлю by people with asthma?

Official labeling advises that patients with respiratory conditions, including asthma, must use the medicine with caution or only after consultation. This caution applies especially if they have chronic cough or emphysema.

---

Q: What is the general difference in how cold remedies like ТераФлю work compared to antivirals?

Cold remedies like this fixed-dose combination are classed as symptomatic treatments, focused on managing discomforts like pain and fever. Antiviral medications, by contrast, are intended to interfere directly with the replication cycle of the viral pathogen.

---

Q: Are there any specific warnings for people who have thyroid issues?

Official regulatory documents state that the medicine is contraindicated for use by individuals diagnosed with hyperthyroidism (overactive thyroid). This classification defines the medicine as inappropriate for use by this population.

---

Q: Do studies suggest ТераФлю helps with nasal congestion?

Regulatory reviews have indicated that findings were mixed regarding the role of the oral decongestant component, Phenylephrine, in nasal congestion relief in some contexts. This means that certainty regarding this specific effect appears low.

---

Q: What are the main components that contribute to pain relief in ТераФлю?

Acetaminophen is the principal component that contributes to pain relief and fever reduction. It is the agent classified as the analgesic and antipyretic in the combination formulation.

---

Q: Why is it recommended to consult a healthcare professional about taking ТераФлю with other cough/cold products?

This warning exists primarily to prevent the accidental overdose of active ingredients, especially Acetaminophen, which is common in many cold/flu products. It also prevents the risk of additive side effects from combining multiple decongestants or sedating components.

Storage and Disposal Requirements for Theraflu

Theraflu powder for oral solution must be stored at controlled room temperature, maintaining a range of 20°C to 25°C (68°F to 77°F). The product must be protected from heat and moisture to preserve its stability. To ensure child safety, the medication must always be kept out of reach of children. The product should not be used if the sealed packet is torn or broken and must be discarded after its printed expiration date.

Disposal Instructions

Unused or expired Theraflu should be disposed of using community-based drug take-back programs. If these programs are unavailable, the medicine may be mixed with an undesirable substance and placed in the household trash. Do not flush medicines down the sink or toilet unless the labeling specifically instructs it.